After reporting initial data earlier this year, investigators presented a fuller analysis in a poster at the 2022 SDPA Annual Fall Dermatology Conference.
Heidi Anne Duerr, MPH
Advertisement
Articles by Heidi Anne Duerr, MPH
The greatest improvements in quality of life measures were seen in the 300 mg tralokinumab group.
Advertisement
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Tildrakizumab for Active Psoriatic Arthritis
2
The Scariest Skin Care Trends Haunting Patients This Halloween
3
Improving Early Identification and Escalation of HS
4
October Social Media Mythbusters: 3 Viral Beauty Claims, Debunked
5